From ProactivetraderStirling operates through three main business units each managed by proven industry specialist managers:
- Pharmaceutical & Healthcare - Research & Development - Animal Products
Stirling Products boosts pharmaceutical exposure by winning Innovative New Product for KidneyVital? Friday, June 17, 2011 by John Phillips
Stirling Products (ASX: STI) has received a major vote of confidence in the company's KidneyVital? product by the pharmaceutical community, with the product receiving the ?Innovative New Product? award.
The award will be presented at the Pharmacy Expo 2011, which is conducted jointly by The Pharmacy Guild of Australia and the Pharmaceutical Society of Australia.
What is so important about the award is the exposure the product will gain, with over 100 exhibitors and 3,000 pharmacy industry attendees at the Expo in Sydney.
KidneyVital? will be launched at the Expo by the company's specialist marketing group Stirling Health.
Importantly the product has gained support from Kidney Health Australia, with the chief executive officer, Anne Wilson, saying, "Kidney Health Australia is delighted to deliver KidneyVital to the Australian pharmacy marketplace in conjunction with our partners Stirling Products.
"This is a major initiative specifically designed for Australia?s 1.7 million people with chronic kidney disease.?
Stirling said based on available clinical studies, KidneyVital? is the first multivitamin product tailored specifically to meet the nutritional needs of people with Chronic Kidney Disease and for those following transplantation.
Chronic Kidney Disease is a significant and growing public health problem that will cost the Australian taxpayer over an estimated $12 billion for the period 2009 to 2020, with the incidence of kidney disease increasing significantly DYOR
STI Price at posting:
0.3¢ Sentiment: Hold Disclosure: Held